CN206385173U - Device for the accurate treatment method of tumour based on CTC circulating tumor cells - Google Patents
Device for the accurate treatment method of tumour based on CTC circulating tumor cells Download PDFInfo
- Publication number
- CN206385173U CN206385173U CN201621378586.6U CN201621378586U CN206385173U CN 206385173 U CN206385173 U CN 206385173U CN 201621378586 U CN201621378586 U CN 201621378586U CN 206385173 U CN206385173 U CN 206385173U
- Authority
- CN
- China
- Prior art keywords
- circulating tumor
- ctc
- tumor cells
- ctc circulating
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The utility model provides a kind of device available for the accurate treatment method of tumour based on CTC circulating tumor cells.Comprise the following steps：CTC circulating tumor cell separation equipments, for separating CTC circulating tumor cells from the peripheral blood added；CTC circulating tumor cell detection devices, the CTC circulating tumor cell separated for detecting；Closed CTC circulating tumor cells culture device, for separated CTC circulating tumor cells to be carried out into vitro culture, propagation；Susceptibility detection device, drug sensitive experiment is carried out for the CTC circulating tumor cells to culture.The application carries out drug sensitivity testing in vitro using the CTC circulating tumor cells of patient, with the accurate therapeutic effect of personalization for patient；The method that the application carries out parallel drug sensitive test, can per it is less preferred go out a clinical application scheme, tumour cell is faced the attack of different type medicine all the time so that tumor conformal answers the ability of medicine to die down, the drug resistance problems that single clinical application can be avoided to produce.
Description
Technical field
The utility model belongs to medical domain, is related to and a kind of is precisely controlled available for the tumour based on CTC circulating tumor cells
The device for the treatment of method.
Background technology
Tumour is the major disease of the world today, and it is big that its high mortality and the complexity treated have promoted countries in the world to spend
The manpower and materials of amount are studied, but the not yet progress of making a breakthrough property so far, by United States Medicine man's Siddhartha Mu Ke
Lucky (Siddhartha Mukherjee) is referred to as the king of many diseases.
The formation of tumour is a multifactor complex process, and this, which makes to study it, becomes increasingly complex.The treatment of tumour
It is to be deployed based on the understanding to tumour, experienced operation, radiotherapy, conventional chemotherapy and targeted drug treatment and heat at this stage
Door research method exempts from-epidemic disease cell therapy.
Operation, as the term suggests it is exactly to cut off macroscopic tumour.The difficult point of the method is that excision and the relation of tumour have
There is uncertainty.Due to the complexity of tumour, especially Advanced cancers, the tissue of patient distant place may have been shifted and soaked
Profit, therefore operation can only cut off a part, it is difficult to cut clean.By taking brain tumor as an example, because naked eyes are difficult to differentiate and cut off less than 1mm
Tumour, and the such grade malignancy of glioma very high tumour cell spreads in normal cerebral tissue, Post operation tumour
It can recur quickly.Secondly, even if cutting totally, such as excision is not primary tumor, then the primary at other positions of body
Tumour can also develop.So, operation at present is only as the recommendation method of an infantile tumour treatment.
Radiotherapy, is exactly, using high-power ray, tumor tissues to be destroyed.The difficult point of the method is how accurately to catch
Tumor tissues, high-precision radiotherapy is carried out to it.It is straight with ray because tissue is D structure even if scope is very accurate
There is the normal structure destruction in depth direction in line irradiation human body, the destruction of minimum degree is not injure tumor tissues rear portion
Normal human tissue.So, radiotherapy is at present only as a kind of a kind of means for mitigating patient symptom, it is impossible to fundamentally prevent swollen
The development of knurl.
Conventional chemotherapy, due to also toxic to normal cell, can cause big to patient's toxic side effect, make patient's constitution obvious
Decline, without possessing the physical qualification of chemotherapy again.The method is used as interim remedy measures, unsustainable treatment.
Targeted drug therapy, is intervened primarily directed to some special gene mutations in tumour cell, to reach suppression
System and the purpose for killing tumour cell.The advantage for targetting medicine is to significantly reduce the toxic side effect that conventional chemotherapy is brought, but is existed
Two difficult points, one is that the tumour cell of many tumour patients does not target the gene mutation of medicine intervention, the trouble for there was only 5% at present
Person can be treated with targeted drug.Even this part of patient, another difficult point of targeting medicine treatment is exactly resistance
Property.Due to the complexity of tumor pathogenesis, one or several target spots do not control tumour at all.Therefore, targeting medicine can only prolong
The progress of slow tumour, it is impossible to fundamentally control tumour.
Tumour immunotherapy, is applied immunology principle and method, and the immunogenicity and pairing effect for improving tumour cell are thin
The sensitiveness of born of the same parents' killing, excites and strengthens antitumor immunity of organism response, and application immunocyte and effector molecule infusion host
In vivo, collaboration body immune system killing tumour, suppresses tumour growth.At present, the medicine of some existing immunotherapy of tumors is obtained
Obtain the approval of U.S. FDA and enter clinical practice.Existing immunization therapy includes the treatment of control point and ACT (adoptive cell
Transfer) cell adoptive therapy.2011, first approved immune control point medicine was Bristol-Myers
The CTLA4 of Squibb companies suppresses monoclonal antibody lpilimumab (Yervoy).When doctor and Medical scientists have new resisting to swell
Tumor medicine, the problem of naturally will recognize that drug combination.As control point inhibitor is immunized in the second generation --- targeting PD-1/PD-
L1 generation, FDA accelerates to have approved large quantities of immune control point medicines, such as pembrolizumab is used to treat maligna
Plain knurl, nirolumab is used to treat melanoma and lung cancer, etc..By PD-1 and CTLA4 Drug combinations, greatly carry
The high objective reactivity of melanoma cancer patients.Because tumor microenvironment has obvious inhibition, so first using immunization card
Control point contact immunosuppressive environment is preferable selection.
The use in conjunction of immunotherapy includes：
(1) so that control point is immunized as key basis selection.Such as：CTLA4 and PD-1 inhibitor is used simultaneously, though because
Right CTLA4 and PD1 is expressed in T cell, but their suppression mechanism is different.CTLA4 and CD28 competitiveness CD80/86 signals
Approach, so that T cell is activated, and PD-1 is expressed on the lymphocyte of activation.
And chemotherapy combined (2).Knurl load first is reduced with chemotherapy, immunotherapy is then carried out.
(3) combine with BRAF inhibitor.
(4) combine with VEGF targeted drugs.
In a word, the purpose that conjoint therapy is immunized is desirable to obtain a prolonged stable curative effect.However, due to tumour
The complexity of formation mechenism, the above application is in clinical research, and its effectiveness to patient is also to be seen.
In summary, tumour is due to its complexity, and traditional treatment means can play a part of fairly limited.It is at present
Only, tumour is that a kind of pathogenesis is not yet clear and definite, and treatment means are extremely limited, and disease becomes
Change various disease combination.Different tumours, the characteristics of having different due to the difference in primary site；It is same swollen
Otherness between knurl, different patients is also very big；With same patient, primary lesion and metastatic lesion, or even same tumour
The diverse location of tissue, the phenotype of tumour cell and gene mutation are all different.Therefore, in therapeutic field of tumor, a kind of system is lacked
System consideration, the various subdivision fields of integration accurate treatment method in terms of patient, treatment and research is raised.
Utility model content
The problem of for easily producing drug resistance in current tumor therapeutic procedure, the utility model can be used for there is provided one kind
The device of the accurate treatment method of tumour based on CTC circulating tumor cells.
The utility model one side, which is to provide, a kind of is used for the accurate side for the treatment of of the tumour based on CTC circulating tumor cells
The device of method, including：
--- shell, the shell is provided with hole, for patient's peripheral blood of extraction to be added；
--- CTC circulating tumor cell separation equipments are thin for separating CTC circulating tumors from the peripheral blood added
Born of the same parents；Preferably, the CTC circulating tumor cells separation equipment is located in the shell；
--- CTC circulating tumor cell detection devices, the CTC circulating tumor cell separated for detecting；Preferably, institute
CTC circulating tumor cells detection device is stated in the shell；
--- closed CTC circulating tumor cells culture device, for separated CTC circulating tumor cells to be carried out
In vitro culture, propagation；Wherein described CTC circulating tumor cells culture device can be located in the shell or position
In the housing exterior；
--- susceptibility detection device, carry out drug sensitive experiment for the CTC circulating tumor cells to culture；Preferably, it is described
Susceptibility detection device can be located in the shell or positioned at the housing exterior.
In a kind of preferred embodiment of the present utility model, the internal cavities of the shell are provided with the reception periphery blood examination
First container of test sample product.First container can be one or more.
It is highly preferred that the first pan straddle is provided with the shell, for placing the first container.It is highly preferred that described
One pan straddle can rotate about axle rotation；First pan straddle is provided with multiple first container standing grooves, one or more
First container standing groove is arranged around the rotary shaft.
It is highly preferred that be provided with the first container removal piece in the shell, for by receive after peripheral blood detection sample the
One container takes out out of described first container standing groove, it is preferable that can be that the modes such as crawl, push are taken out.
In a kind of preferred embodiment of the present utility model, described device includes the first container transfer device, for by institute
The first container is stated to transmit to CTC circulating tumor cells separation equipment.It is highly preferred that the first container removal piece will be taken out
First container is placed into the first container transfer device.
In a kind of preferred embodiment of the present utility model, described device includes second container, is separated for receiving
CTC circulating tumor cells.
In a kind of preferred embodiment of the present utility model, described device includes second container transmission equipment, for by institute
State second container and successively or be respectively transmitted to CTC circulating tumor cells detection device, CTC circulating tumor cells culture device.
It is highly preferred that the second container transmission equipment includes first end removal piece, for taking out, placing by second container
On second container transmission equipment；And/or the second container transmission equipment includes the second end removal piece, for by second container
Second container on transmission equipment takes out, and is placed into CTC circulating tumor cells detection device and/or the training of CTC circulating tumor cells
Support in equipment.
It is highly preferred that the CTC circulating tumor cells detection device and/or the culture of CTC circulating tumor cells are provided with second
Pan straddle, for placing second container.It is highly preferred that the second container is multiple, the second container support can be around it
Rotary shaft is rotated；The second container support is provided with multiple second container standing grooves, and multiple second container standing grooves are around described
Rotary shaft is arranged.
In a kind of more preferred embodiment of the present utility model, the CTC circulating tumor cells culture device and the medicine
Quick detection device is integrated to be set, for example, the CTC circulating tumor cells culture device is shared with the susceptibility detection device
One can closed chamber, it is described that thermoregulator, content of nitrogen dioxide detector, gas turnover can be provided with closed chamber
Mouth, liquid material add mouth.
In a kind of more preferred embodiment of the present utility model, it is described can closed chamber be provided with watch window, the observation
Window can be integrally fixed at can be in closed chamber transparent window or can stretch into it is described can closed chamber camera lens.Or
Person, in another more preferred embodiment, it is described can closed chamber provided with shooting and/or photographing device.Wherein, the shooting
And/or photographing device can substitute watch window, can also simultaneously exist with the watch window.
In a kind of preferred embodiment of the present utility model, the CTC circulating tumor cells separation equipment, CTC circulations are swollen
Oncocyte detection device is located in the shell, the CTC circulating tumor cells culture device and susceptibility detection device position
In the outside of shell, and shared one can closed chamber.
In a kind of more preferred embodiment of the present utility model, provided with it is multiple can closed chamber, each can closed chamber
It is interior that one or more CTC circulating tumor cells culture devices and the susceptibility detection device are set.
In more preferred embodiment, provided with transport channel by it is the multiple can closed chamber connect, for by second container
Feeding is expected can be in closed chamber.
In a kind of preferred embodiment of the present utility model, described device includes processor, data output apparatus, the place
Manage device and manipulate data output apparatus by CTC circulating tumor cells testing result and/or the output of drug sensitive experiment result, or the place
CTC circulating tumor cell testing results can be converted to disease condition and/or can be converted to drug sensitive experiment result by reason device
Patients clinical medication guide scheme is exported.
In a kind of preferred embodiment of the present utility model, described device also includes holder, and patient is come from for storing
The detection data of each peripheral blood sample, it is preferable that the detection data are at least including any one in following data or several
Kind：CTC circulating tumor cells testing result, disease condition, CTC circulating tumor cell resistances situation, therapeutic regimen, repetition are detected
Number of times.
In a kind of preferred embodiment of the present utility model, before each peripheral blood sample detection and/or after detection, the place
The detection data that device reads the peripheral blood sample before of same patient are managed, and is contrasted and/or exported in the lump with it.
In a kind of preferred embodiment of the present utility model, the volume of first container, no less than 5ml, is preferably not
Less than 5ml, generally preferably 5-10ml, more preferably 6-9ml, preferably 7-8.5ml, 7.5-8ml.
Second aspect of the present utility model is to provide a kind of tumour based on CTC circulating tumor cells precisely side for the treatment of
Method, comprises the following steps：
Step 1：Extract patient's peripheral blood；
Step 2：Separate CTC circulating tumor cells；
Step 3：Pass through CTC circulating tumor cell evaluation disease conditions；
Step 4：CTC circulating tumor cells in vitro culture, propagation；
Step 5：Parallel drug sensitive experiment, and preferably therapeutic regimen is selected according to CTC circulating tumor cell resistance situations；
Step 6：By the therapeutic regimen selected, for instructing patients clinical medication；
Step 7：After one course for the treatment of, patient's peripheral blood is extracted；
Step 8：Separate CTC circulating tumor cells；
Step 9：Assess, if detection CTC circulating tumor cells, repeat step 4- steps 9；If not detecting CTC circulations
Tumour cell, is continuing with clinical application scheme, until not detecting CTC circulating tumor cells again after a period of time.
Wherein, in described step 1, the amount for extracting patient's peripheral blood is not recommended to be less than 5ml, is preferably not less than
5ml, preferably 5-10ml, more preferably 6-9ml, preferably 7-8.5ml, generally 7.5-8ml.
In a kind of preferred embodiment of second aspect of the utility model, methods described uses first aspect described device
Implement.
In a kind of preferred embodiment of second aspect of the utility model, methods described includes：
Step 1：Extract patient's peripheral blood；And peripheral blood sample is added to one or more first containers；
Step 2：CTC circulating tumor cells are separated from the peripheral blood sample of the first container, and the CTC circulations of separation is swollen
Oncocyte is added to second container；
Step 3：Pass through CTC circulating tumor cell evaluation disease conditions；
Step 4：Second container is sent into CTC circulating tumor cell culture devices, CTC circulating tumor cells is carried out and trains in vitro
Support, breed；
Step 5：Parallel drug sensitive experiment, and preferably therapeutic regimen is selected according to CTC circulating tumor cell resistance situations；
Step 6：By the therapeutic regimen selected, for instructing patients clinical medication；
Step 7：After one course for the treatment of, patient's peripheral blood is extracted；
Step 8：Separate CTC circulating tumor cells；
Step 9：Assess, if detection CTC circulating tumor cells, repeat step 4- steps 9；If not detecting CTC circulations
Tumour cell, is continuing with clinical application scheme, until not detecting CTC circulating tumor cells again after a period of time.
In a kind of preferred embodiment of the present utility model, the method for separation CTC circulating tumor cells can be：Pass through thing
Reason characteristic is separated, biological nature is separated, or both separation methods combination, for example can by volume,
Density, charging property and the physical property such as structural separate CTC circulating tumor cells with other cells in blood.
Wherein, the method separated by physical characteristic includes：1) leucocyte is smaller than CTC circulating tumor cell, so
The filter membrane in 8 μm of apertures can be used to remove leucocyte.2) Ficoll (ficoll) or other similar density gradient medias can be used
CTC circulating tumor cells are separated with the monocyte in red blood cell and blood plasma.3) because CTC circulating tumor cells are relative to blood
The volume and non-deformability of other cells in liquid are higher, microchip can be used to catch CTC circulating tumor cells, pass through afterwards
Dielectrophoresis (DEP) is separated according to the charge property of CTC circulating tumor cells.
Wherein, the method separated by biological nature includes：Positive selection and the class of negative selection two, it can be by immune
Method or microfluidic methods are realized.Antibody positive selection method uses the anti-interstitials such as the epithelium such as EpCAM mark, N- cadherins
The anti-epithelial cell such as label or plastin3 and mesenchyma label.Negative selection rule is removed white using anti-CD45 antibody
Cell.
The preferred antibody mixed liquor of different tumor types is aimed in addition, being preferably used during separation, it is ensured that obtained as many as possible
Tumour cell.Such as：The Adna Test CancerSelect of QIAGEN companies use magnetic bead binding antibody from tumour patient
Blood sample in separate tumour cell.
In a kind of preferred embodiment of the present utility model, the CTC circulating tumor cells testing result at least includes CTC
Quantity (number), characteristic type of circulating tumor cell etc..The CTC circulating tumor cells testing result can also be included to dividing
Separate out the CTC circulating tumor cells come and carry out Activity determination, to judge its activity having.
In a kind of preferred embodiment of the present utility model, the culture of described CTC circulating tumor cells, propagation, it is led
It is the environment in simulation patient's body as far as possible to want condition.In terms of CTC circulating tumor cells in vitro culture and multiplication technique, it is led
It is nonpollution environment, stationary temperature, the environment of gas, cell culture fluid PH concentration and cell culture medium to want condition.
The temperature of described CTC circulating tumor cell cultures is preferably 36.5 DEG C ± 0.5 DEG C.
It is preferably to contain CO in the gaseous environment of described CTC circulating tumor cell cultures2。
In a kind of preferred embodiment of the present utility model, the cell culture fluid of described CTC circulating tumor cell cultures
Middle addition NaHCO3, it is possible to provide CO2；Hydroxyethyl piperazine second thiosulfonic acid (HEPES) can also be added in the cell culture fluid, its
To cytotoxic, cushioning effect is also played, there is the characteristic for preventing PH from changing rapidly, and is used in open cells culture technique, its
Great advantage is to maintain more constant pH value in open culture or cell observation.
The cell culture medium of described CTC circulating tumor cell cultures is to cultivate to supply cytotrophy in cell and promote thin
The basic substance of born of the same parents' propagation, is also the living environment for cultivating cell growth and propagation.It is preferable to carry out in one kind of the present utility model
In example, cell culture medium uses synthetic media and/or natural medium.Synthetic media is the material according to required for cell
Type and quantity strictly configuration, interior carbohydrate containing, amino acid, lipid, inorganic salts, vitamin, trace element and
Porcine HGF etc..Natural medium uses calf serum.Calf serum contains various kinds of cell growth factor, promotees to attach the factor
And its many active materials, shared with synthetic media, cell can be made smoothly to breed growth.
In a kind of preferred embodiment of the present utility model, the drug sensitive test is preferably parallel drug sensitive experiment, Ji Jiangjing
The CTC circulating tumor cells of in vitro culture propagation carry out the parallel sensitization test of one group of medicine.The medicine is over the course for the treatment of
It is recommended that the medicine ratified using FDA, can also be used, but be preferably used for research without the FDA medicines ratified.Same group of medicine
The selection of thing is open, including various chemotherapeutics, targeted drug and biological agent etc., and it is with can be same type in group
Different pharmaceutical or different types of drug regimen.The drug sensitivity test can use atriphos bioluminescence
Method (ATP-TCA) and collagen gel drop embedding culture Antibiotics resistance test method (CD-DST) are carried out.
The preferably therapeutic regimen, can draw according to different above-mentioned test methods.Ordinary priority selects cell to medicine
The sensitive therapeutic regimen of thing, can be the combination of single medicine or several drugses.More preferably simultaneously toxic side effect it is small use prescription
Case.
Medicine used in the parallel drug sensitive experiment is preferably selected from：Mustargen, n-formyl sarcolysine, endoxan, ifosfamide, benzene fourth
Sour mustargen, thio-tepa, busulfan, hexamethyl melamine, melphalan, BCNU, Semustine, Fotemustine, Nimustine, Lip river are not
Take charge of spit of fland, Nitrocaphane, cis-platinum, carboplatin, oxaliplatin, methotrexate (MTX), fluorouracil, Tegafur, Tegafur-uracil mixt., Tegafur-
Uracil, doxifluridine, Carmofur capecitabine, mercaptopurine, thioguanine, hydroxycarbamide, cytarabine, gemcitabine, fluorine
Up to drawing shore, it is Aclarubicin, SN-11841, THP, epirubicin, Doxorubicin, actinomycin D, mitoxantrone, soft red mould
Element, mitomycin, bleomycin, bleomycin A5, idarubicin, Irinotecan, Hydroxycamptothecin, eldisine, vincaleukoblastinum, Changchun
Rui Bin, vincristine, taxol, homoharringtonine, cantharidin, Norcantharidin, L-Asparaginasum, Pegaspargase, Ah that
Bent azoles, aminoglutethimide, Nilutamide, Nandrolone Phenylpropionate, Bicalutamide, testosterone propionate, Buserelin, DANAZOL, dexamethasone,
Flutamide, formestane, compound testosterone ester, Leuprorelin, Gonadorelin, Goserelin, nafarelin, Triptorelin, progesterone,
Diethylstilbestrol, megestrol acetate, methyltestosterone, methylprednisolone, Medroxyprogesterone, thyroid tablet, levothyroxine sodium, Letrozole, meter Tuo
Smooth, Chlorotrianisene, spirolactone, metacortandracin, prednisolone, hydrocortisone, ethinyloestradiol, TAM, Exemestane, Bali former times
Monoclonal antibody, Avastin, Rituximab, Victibix, Herceptin, ibritumomab tiuxetan, Cetuximab, boron are for assistant
Rice, Lapatinib, Sutent, proleulzin, recombinantinterferonα, recombinant interferon β -1 α, restructuring adenovirus hominis, shellfish Bimbisara
Spit of fland, Dasatinib, indigo red, Tarceva, fulvestrant, Gefitinib, Meisoindigotin, lenalidomide, Clofazimine, Clodronate
Disodium, 7-chloro-4-oxo-quinoline, Miltefosine, Pamidronate Disodium, pemetrexed, arsenic trioxide, amine, Sorafenib, dimension A in short-tube lycoris
Acid, thymosin extrasin, Thymopentin, endostatin research, ibandronic acid, Imatinib, zoledronic acid, abarelix, acetic acid Ah ratio
Special dragon ester, Herceptin-Ematansine conjugates, Afatinib, alemtuzumab, Ali's Tretinoin, Erwinia chrysanthemi door winter acyl
Amine enzyme, Axitinib, azacitidine, bendamustine hydrochloride, Bexarotene, SKI-606, Cabazitaxel, card are rich for Buddhist nun, card
Fei Zuo meter, choline C11, cinacalcet hydrochloride, clofarabine, Da Lafeini, Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Lys(iPr)-Pro-D-Ala-NH2, denileukin diftitox, Di Nuosaimai,
En Zhalu amine, methanesulfonic acid eribulin, paddy block an enzyme, ibritumomab tiuxetan, replace Buddhist nun, easy Puli's nurse agate, Ipsapirone, meter Tuo according to Shandong
His pungent, Victibix, pazopanib, Pegademase, spray department of smooth, nelarabine, 99- mtc labeled anticancers monoclonal antibody, difficult to understand, U.S. amber
Statin, handkerchief trastuzumab, pomalidomide, handkerchief are received for Buddhist nun, Porfimer Sodium, Pralatrexate, radium chloride -223, rasburicase, Rui Ge
Non- Buddhist nun, romidepsin, gland secretin, streptozotocin, CCI-779, Sibutramine Hydrochloride replace Buddhist nun, valrubicin, ZD6474, Wei Luofeini, dimension
Mo Deji, Vorinostat, VEGF Trap, Tbo-filgrastim, Technetium 9Tc 99m tilmanocept,
Obinutuzumab、Brentuximab Bedotin、Buffered Intrathecal Electrolyte/Dextrose。
It should be appreciated that the selection of said medicine, is preferably to carry out drug sensitive experiment with reference to clear and definite indication.
Device provided by the utility model, with advantages below：
1st, the treatment and assessment of tumour are carried out using CTC circulating tumor cells, the influence very little to patient (only extracts patient
5-10ml peripheral blood).
2nd, drug sensitivity testing in vitro is carried out using the CTC circulating tumor cells of patient, with the personalization for patient precisely
Therapeutic effect.
3rd, the method that parallel drug sensitive test is carried out using different clinical medicines, can per it is less preferred go out a clinical application side
Case, makes tumour cell face the attack of different type medicine all the time, so that tumor conformal answers the ability of medicine to die down, can avoid list
The drug resistance problems that one clinical application is produced.
4th, the therapeutic progresses of circulation and the clinical medicine selecting method of opening can be achieved, there is this treatment method sustainable
Property and expansionary.
5th, treatment is combined with assessment, and the assessment time is shorter, is conducive to carrying out patient quick screening clinical application,
Into personalized treatment；
6th, device described in the utility model can realize ill assessment, the procedure of screening clinical application, and preferably
Ground can realize the detection and report output of multiple patient samples.
Brief description of the drawings
Fig. 1 be a kind of embodiment of the utility model in be used for the accurate treatment method of tumour based on CTC circulating tumor cells
Device external structure schematic diagram；
Fig. 2 is the first pan straddle or second container supporting structure schematic diagram in a kind of embodiment of the utility model；
Fig. 3 be a kind of embodiment of the utility model in be used for the accurate treatment method of tumour based on CTC circulating tumor cells
Device the first container, second container conveying schematic diagram.
Embodiment
As shown in figs. 1 and 3, it is described in the utility model to be used for the precisely side for the treatment of of the tumour based on CTC circulating tumor cells
The device of method, including shell 1, the wall of shell 1 are provided with peripheral blood sample well 12 and data display screen 11, shell
Provided with processor (not shown), CTC circulating tumor cells separation equipment 6, the first pan straddle 2.
As shown in Figures 2 and 3, the first pan straddle 2 includes the main body 21 of disc or cylinder, and the center of main body 21 is
Rotary shaft 23, revolves around it axle 23 and the first container standing groove 22 is distributed with, multiple first containers 20 are placed in the first container standing groove
In 22.
Extract to the peripheral blood sample of patient, be added to by shell 1 in the first container 20, sometimes, it is necessary to multiple samples
In the case of product, after the charging of each first container 20, the first pan straddle 2 is rotated around rotary shaft 23, and next first is held
Device 20 is placed in the lower section of peripheral blood sample well 12, and subsequent sample is gradually added.
After sample-adding is finished, the first container 20 for holding peripheral blood sample is placed into the transmission of the first container and set by handgrip 72 one by one
Standby 3, Fig. 3 shows a kind of capture apparatus containing two handgrips 72, and two handgrips 72 are connected by turning arm 71, but also may be used
To be 1 or more handgrip, in the case that turning arm 71 rotates, multiple handgrips 72 take out the first container 20 alternation
And it is placed into the first container transfer device 3.First container is sent into CTC circulating tumor cells and separated by the first container transfer device 3
Equipment 6, CTC circulating tumor cells are separated from peripheral blood sample.
Separate CTC methods numerous, but can generally be classified as two major classes：Separated by physical characteristic and biological nature.It is real
In the operation of border, both principles can be combined by most separation methods.
Separated by physical characteristic, can be by CTC by size, density, charging property and these structural physical properties
Separated with other cells in blood.Leucocyte is smaller than CTC, so the filter membrane in 8 μm of apertures can be used to remove leucocyte.It can be used
Ficoll (ficoll) or other similar density gradient medias separate CTC with the monocyte in red blood cell and blood plasma.Cause
CTC is higher relative to the volume and non-deformability of other cells in blood, microchip can be used to catch CTC, passes through afterwards
Dielectrophoresis (DEP) is separated according to CTC charge property.
CTC biological nature separation includes positive selection and the class of negative selection two, can pass through immunization method or microfluidic methods
Realize.Antibody positive selection method uses the epithelium mark such as EpCAM, anti-mesenchymal or the plastin3 such as N- cadherins
Etc. anti-epithelial cell and mesenchyma label.Negative selection rule removes leucocyte using anti-CD45 antibody.No matter what is used
The method of kind, operation scheme must be followed strictly during the cell of the such negligible amounts of separating trap.
The preferred antibody mixed liquor of different tumor types is aimed in addition, should be used during separation, it is ensured that obtained as much as possible
Tumour cell.Such as：Adna Test CancerSelect under QIAGEN use magnetic bead binding antibody from tumour patient
Tumour cell is separated in blood sample.
CTC circulating tumor cells after separation are placed in multiple second containers 511, wherein one or more second containers 511
Sample pass through CTC circulating tumor cell detection device (not shown)s.CTC circulating tumor cells detection project includes CTC number
Measure (number), characteristic type etc. directly can carry out or be delivered to list in CTC circulating tumor cells separation equipment 6
Detected in the CTC circulating tumor cell detection devices solely existed.Processor will be detected and assessment result is exported by display screen 11,
Or can also export result including printer etc..
With advances in technology, CTC circulating tumor cells detection technique can carry out the research of CTC characterization of molecules.It can pass through
CTC characterization of molecules before and after treatment compares, and carries out the course of disease analysis and research, such as drug resistance of CTC circulating tumor cells of patient
Problem.Assessing also includes carrying out activity research to the CTC circulating tumor cells separated, to judge its activity having.
Remaining second container 511 delivers to CTC circulating tumor cells culture device 5 by second container conveying equipment 4.
CTC circulating tumor cells culture device 5 can be multiple unit compositions, and a unit is used alone in the sample of each patient,
As shown in figure 1, at least including connecting by transmission equipment 50 between three units 51,52 and 53, unit, second container
511 are delivered in expected unit by transmission equipment 50.
As shown in figure 3, being provided with second container support 510, its structure and first in CTC circulating tumor cells culture device 5
Pan straddle is same or like, including center rotary shaft 513, revolve around it axle 513 distribution second container standing groove
512.Second container 511 is taken out and is placed into second container standing groove 512 by handgrip 72.
Essential condition is the environment in simulation patient's body as far as possible in CTC circulating tumor cells culture device 5.It is thin in CTC
Born of the same parents' in vitro culture and multiplication technique aspect, its essential condition are nonpollution environment, stationary temperature, the environment of gas, cell training
Nutrient solution PH concentration and cell culture medium.
Nonpollution environment, nontoxic and sterile culture environment is the most important condition for ensureing CTC cells survivals.When CTC cells are put
When being placed in vitro culture, with vivo compared to cell loss to microorganism and the defence capability of Toxic, once it is contaminated or oneself
Body metabolite accumulation etc., can cause cell death.Therefore, in being cultivated, cells survival environmental nonpollution, metabolism are kept
Thing removing etc. in time, is the primary condition for maintaining cells survival.
Stationary temperature：Maintain culture cell vigorous growth, it is necessary to have constant suitable temperature.Cultivate the most thermophilic of cell
Spend the normal temperature for body of being drawn materials equivalent to various cell or tissues.The normal temperature of CTC cell culture is 36.5 DEG C ± 0.5
DEG C, deviate this temperature range, the eubolism of cell can be affected, in addition it is dead.
Gaseous environment：Gas is the requirement of CTC cell culture existence, and required gas mainly has oxygen and titanium dioxide
Carbon.Oxygen participate in tricarboxylic acid cycle, produce supply growth and proliferation of cell energy and synthetic cell growth required for it is various into
Point.During open culturing, CTC cell is placed in 95% air plus 5% carbon dioxide gas mixture environment.Carbon dioxide is both
Products of cellular metabolism, is also composition needed for cell growth breeding, and its main function in cell culture also resides in maintenance culture medium
PH value.
Cell culture fluid PH concentration：Add NaHCO3, it is possible to provide CO2, but CO2It is easy to effusion, therefore is best suited for closing training
Support；And hydroxyethyl piperazine second thiosulfonic acid (HEPES) also plays cushioning effect because it is to cytotoxic, prevent PH from changing rapidly
Characteristic, and be used in open cells culture technique, its great advantage be can be maintained in open culture or cell observation compared with
Constant pH value.
Cell culture medium：Culture medium is to cultivate supply cytotrophy and the basic substance for promoting cell to breed in cell,
It is the living environment for cultivating cell growth and propagation.Culture medium uses synthetic media and natural medium.Synthetic media is
The type and quantity of the material strictly configuration according to required for cell, it is interior carbohydrate containing, amino acid, lipid, inorganic
Salt, vitamin, trace element and Porcine HGF etc..Natural medium uses calf serum.Calf serum contains a variety of thin
The intracellular growth factor, rush attach the factor and its many active materials, shared with synthetic media, cell can be made smoothly to breed growth.
In incubation and after the completion of culture, by shooting and/or photographing device, or by observation window, cell is observed
Culture, proliferative conditions.
After the completion of culture, with reference to peripheral blood sample sample loading alternative, CTC circulating tumor cells culture device 5 adds provided with medicine
Sample hole, medicine is added by the medicine well into second container 511.Second container support 510 rotates, one by one by each
Second container 511 is placed in below medicine well, and different medicines are added in each second container 511, carries out parallel susceptibility real
Test, observe drug sensitive experiment result.
In the utility model device, holder can also be included, by drug sensitive experiment result, disease condition, once used
The information such as medicine (medicine for especially having produced drug resistance) stored, each time before drug sensitive experiment, by letter before
Breath is read, and can avoid the drug sensitive experiment of repeatability, is tested after terminating, and can also be contrasted with information before, judges treatment feelings
Condition simultaneously selects preferably therapeutic regimen.
The parallel drug sensitive test is the parallel sensitive examination that the CTC cells that will breed through in vitro culture carry out one group of medicine
Test.The medicine advises the medicine ratified using FDA over the course for the treatment of, only supplies to be used to study without the FDA medicines ratified.Together
The selection of one group of medicine is open, including various chemotherapeutics, targeted drug and biological agent etc., and it is with can be same in group
The different pharmaceutical of type or different types of drug regimen.The drug sensitivity test can be using atriphos life
Thing luminescence method (ATP-TCA) and collagen gel drop embedding culture Antibiotics resistance test method (CD-DST) are carried out.It is preferred that parallel
Testing program, can draw according to different above-mentioned test methods.
Embodiment 1
Using device described in the utility model, the utility model additionally provides a kind of based on CTC circulating tumor cells
The accurate treatment method of tumour, comprises the following steps：
Step 1：Extract certain breast cancer patients 5-10ml peripheral bloods
Extraction patient's 5-10ml peripheral bloods, typically extract 7.5ml, do not recommend to be less than 5ml.The storage and transport of blood
It must be carried out within recommended temperature range, i.e., 4 DEG C to 10 DEG C refrigerations, or 15 DEG C to 30 DEG C of room temperature environment, blood can not be freezed,
It is added in the first container.
Step 2：Separate CTC circulating tumor cells
Described separation CTC circulating tumor cells should be specified in the time after blood drawing and completed, and typically press CTC separation methods
It is different and different, may be a few hours or a couple of days.If it exceeds the time of specifying, under conditions of it there is anti-coagulants, some
Blood coagulation and caking may also occur in blood sample.
CTC circulating tumor cells after separation are added to second container.
Step 3：Assess
Before either treating or after treatment, CTC quantity is main reference index.Clinical research confirmation：Work as blood sample
In CTC be higher than cut-off (>=5/7.5ml) when prompting prognosis it is bad, when the CTC in sample be less than the threshold value (cut-
Off prognosis bona) is then pointed out.What is more important, after treatment is taken, the CTC quantity before contrast treatment, it will help judge
The development of patient disease or treatment situation.
CTC quantity is raised, and points out curative effect bad；And CTC quantity declines, point out curative effect preferable.It is this it is real-time, sensitive, can
The appraisal procedure leaned on can help doctor correctly to judge curative effect and formulate efficient individualized treatment scheme.CTC is assessed than tradition
Iconography earlier, more accurate, more delicately judging prognosis.Numerous studies show：Monitoring CTC after 4 weeks is treated for prognosis to sentence
Judged result of the disconnected result with traditional iconography after treating 12 weeks is extremely coincide.Moreover, when CTC numerical value is more than or equal to cut-
During off values, it is more accurate than iconography for Index for diagnosis that CTC is assessed.
Assessment result is exported by display screen, is referred to for doctor.
Step 4：CTC circulating tumor cells in vitro culture, propagation
CTC circulating tumor cells feeding CTC circulating tumor cell culture devices in second container, carry out in vitro culture increasing
Grow.
Step 5：Parallel drug sensitive experiment, preferably wherein a scheme
Presentation of information in holder, the patient produces resistance to endoxan, ifosfamide, Exemestane medicine
Property, therefore, during drug sensitive experiment, above-mentioned three kinds of medicines are excluded, select following medicine to carry out parallel drug sensitive experiment：It is thio-tepa, American and French
Logical sequence, methotrexate (MTX), fluorouracil, Tegafur-uracil mixt., doxifluridine, Tegafur, Carmofur, UFT, card training
His shore, Aclarubicin, THP, epirubicin, Doxorubicin, mitoxantrone, mitomycin, bleomycin A5, eldisine,
Vincaleukoblastinum, vincristine, taxol, Anastrozole, aminoglutethimide, Nandrolone Phenylpropionate, Buserelin, formestane, compound testosterone
Ester, Gonadorelin, Goserelin, progesterone, diethylstilbestrol, megestrol acetate, Medroxyprogesterone, Letrozole, Leuprorelin, metacortandracin
Dragon, hydrocortisone, Triptorelin, ethinyloestradiol, TAM, Toremifene, Lapatinib, Rituximab, toltrazuril list
Anti-, proleulzin, fulvestrant, recombinant interferon β -1 α, 7-chloro-4-oxo-quinoline.
Drug sensitive test result shows that vincristine, taxol, recombinant interferon β -1 α have optimal suppression tumour cell
Growth result.
Step 6：By preferred parallel drug sensitive experiment scheme, patients clinical medication is instructed
It is described to instruct patients clinical therapeutic regimen to be to draw preferred scheme based on step 5, that is, select vincristine, taxol
Medicine is used as with recombinant interferon β -1 α.Doctor have selected taxol as medicine, and its medication guide is with reference to selected
The operation instruction of clinical medicine is carried out.
Step 7：After one course for the treatment of, patient's 5-10ml peripheral bloods are extracted
The time of a described course for the treatment of, depending on the clinical medicine operation instruction selected in step 6.Described extraction
The quantity of patient's 5-10ml peripheral bloods, the quantity that Ying Yuqian once extracts patient's peripheral blood is consistent, such as same to extract 7.5ml.
It is to have a unified contrast condition to carry out CTC assessments before and after treating using unified peripheral blood extraction amount.
Step 8：Separate CTC circulating tumor cells
The separation CTC circulating tumor cells, method is with step 2, using same separation method and condition, to carry out
CTC, which is assessed, before and after treatment a unified contrast condition.
Step 9：Assess
Appraisal procedure, condition described in step 9 are all carried out according to step 3, also for unified appraisal procedure.At one section
Between do not detect CTC when assessing, can determine that course for the treatment of progress is good, point out the diffusion of patient's tumour to be controlled.Described a period of time,
Depending on the state of an illness and medicine, continuous three treatment times of clinical medicine generally used are advisable.I.e. generally, continuous three
After the individual clinical medicine course for the treatment of used do not detect when CTC circulating tumor cells are assessed, you can be determined as that the state of an illness obtains stabilization
Control.Once detecting CTC, 4 will be repeated the above steps, into CTC circulating tumor cells in vitro culture, amplification step, Jin Erji
Continuous step 5-9 all flows, into diagnosis and treatment circulation.Once, it is secondary not detect CTC, can continue to adopt preferred clinic
Therapeutic regimen.
The patient does not detect CTC, the therapeutic regimen before can continuing.
Embodiment 2
Second embodiment of the accurate treatment method of the tumour described in the utility model based on CTC circulating tumor cells,
Comprise the following steps：
Step 1：Extract prostate cancer patient's 5-10ml peripheral bloods
Extraction patient's 5-10ml peripheral bloods, typically extract 7.5ml, do not recommend to be less than 5ml.The storage of blood and fortune
It is defeated to be carried out within recommended temperature range, i.e., 4 DEG C to 10 DEG C refrigerations, or 15 DEG C to 30 DEG C of room temperature environment, blood can not be cold
Freeze.
Step 2：Separate CTC circulating tumor cells
Described separation CTC circulating tumor cells should be specified in the time after blood drawing and completed, typically by CTC separation methods not
It is different together, may be a few hours or a couple of days.If it exceeds the time of specifying, under conditions of it there is anti-coagulants, some blood
Blood coagulation and caking may also occur in liquid sample.
Step 3：Assess
Clinical research confirmation：When the CTC in blood sample is higher than cut-off (>=5/7.5ml), prompting prognosis is bad, works as sample
CTC in this then points out prognosis bona less than threshold value (cut-off).What is more important, after treatment is taken, before contrast treatment
CTC quantity, it will help judge patient disease development or treatment situation.
CTC quantity is raised, and points out curative effect bad；And CTC quantity declines, point out curative effect preferable.It is this it is real-time, sensitive, can
The appraisal procedure leaned on can help doctor correctly to judge curative effect and formulate efficient individualized treatment scheme.CTC is assessed than tradition
Iconography earlier, more accurate, more delicately judging prognosis.Numerous studies show：Monitoring CTC after 4 weeks is treated for prognosis to sentence
Judged result of the disconnected result with traditional iconography after treating 12 weeks is extremely coincide.Moreover, when CTC numerical value is more than or equal to cut-
During off values, it is more accurate than iconography for Index for diagnosis that CTC is assessed.CTC is assessed preferably to be sentenced than single biological marker
Disconnected curative effect and prognosis.Research shows：In prostate cancer, the judgement that CTC is assessed for prognosis is more accurate than traditional label PSA
It is really and sensitive.
Step 4：CTC circulating tumor cells in vitro culture, propagation
Step 5：Parallel drug sensitive experiment, preferably wherein a scheme
Following medicine is selected to carry out parallel drug sensitive experiment：Cis-platinum, Tegafur, Carmofur, Doxorubicin, mitoxantrone, cloth
Give up Rayleigh, DANAZOL, Flutamide, Gonadorelin, Goserelin, progesterone, diethylstilbestrol, megestrol acetate, Medroxyprogesterone, fluorine alkene
Female ether, nafarelin, Nilutamide, prednisolone, hydrocortisone, Triptorelin, ethinyloestradiol, TAM.
Wherein, Buserelin, that TAM shares scheme works is optimal.
Step 6：By preferred parallel drug sensitive experiment scheme, patients clinical medication is instructed
It is described to instruct patients clinical therapeutic regimen to be to show that preferred scheme, i.e. Buserelin, TAM are closed based on step 5
With.Its medication guide is carried out with reference to the operation instruction of selected clinical medicine.
Step 7：After one course for the treatment of, patient's 5-10ml peripheral bloods are extracted
The time of a described course for the treatment of, depending on the clinical medicine operation instruction selected in step 6.Described extraction
The quantity of patient's 5-10ml peripheral bloods, the quantity that Ying Yuqian once extracts patient's peripheral blood is consistent, such as same to extract 7.5ml.
It is to have a unified contrast condition to carry out CTC assessments before and after treating using unified peripheral blood extraction amount.
Step 8：Separate CTC circulating tumor cells
The separation CTC circulating tumor cells, method is with step 2, using same separation method and condition, to carry out
CTC, which is assessed, before and after treatment a unified contrast condition.
Step 9：Assess
(1) a period of time does not detect CTC, and the state of an illness is controlled, and patient enters observation state；(2) detect CTC, repeat with
Upper step 4 and later step；(3) CTC is not detected, is continuing with clinical application scheme.
Appraisal procedure, condition described in step 9 are all carried out according to step 3, also for unified appraisal procedure.At one section
Between do not detect CTC when assessing, can determine that course for the treatment of progress is good, point out the diffusion of patient's tumour to be controlled.Described a period of time,
Depending on the state of an illness and medicine, continuous three treatment times of clinical medicine generally used are advisable.I.e. generally, continuous three
After the individual clinical medicine course for the treatment of used do not detect when CTC circulating tumor cells are assessed, you can be determined as that the state of an illness obtains stabilization
Control.Once detecting CTC, 4 will be repeated the above steps, into CTC circulating tumor cells in vitro culture, amplification step, Jin Erji
Continuous step 5-9 all flows, into diagnosis and treatment circulation.Once, it is secondary not detect CTC, can continue to adopt preferred clinic
Therapeutic regimen.
The patient does not detect CTC circulating tumor cells, is used for scheme before continuity.
Embodiment 3
3rd embodiment of the accurate treatment method of the tumour described in the utility model based on CTC circulating tumor cells,
Comprise the following steps：
Step 1：Extract colon cancer patient 5-10ml peripheral bloods
Extraction patient's 5-10ml peripheral bloods, typically extract 7.5ml, do not recommend to be less than 5ml.The storage and transport of blood
It must be carried out within recommended temperature range, i.e., 4 DEG C to 10 DEG C refrigerations, or 15 DEG C to 30 DEG C of room temperature environment, blood can not be freezed.
Step 2：Separate CTC circulating tumor cells
Described separation CTC circulating tumor cells should be specified in the time after blood drawing and completed, and typically press CTC separation methods
It is different and different, may be a few hours or a couple of days.If it exceeds the time of specifying, under conditions of it there is anti-coagulants, some
Blood coagulation and caking may also occur in blood sample.
Step 3：Assess
Before either treating or after treatment, CTC quantity is main reference index.Clinical research confirmation：Work as blood sample
In CTC be higher than cut-off (>=3/7.5ml) when prompting prognosis it is bad, when the CTC in sample be less than threshold value (cut-off)
Then point out prognosis bona.What is more important, after treatment is taken, the CTC quantity before contrast treatment, it will help judge patient
Advancing of disease or treatment situation.
CTC quantity is raised, and points out curative effect bad；And CTC quantity declines, point out curative effect preferable.It is this it is real-time, sensitive, can
The appraisal procedure leaned on can help doctor correctly to judge curative effect and formulate efficient individualized treatment scheme.CTC is assessed than tradition
Iconography earlier, more accurate, more delicately judging prognosis.Numerous studies show：Monitoring CTC after 4 weeks is treated for prognosis to sentence
Judged result of the disconnected result with traditional iconography after treating 12 weeks is extremely coincide.Moreover, when CTC numerical value is more than or equal to cut-
During off values, it is more accurate than iconography for Index for diagnosis that CTC is assessed.
Step 4：CTC circulating tumor cells in vitro culture, propagation
Step 5：Parallel drug sensitive experiment, preferably wherein a scheme
The patient is to Oxaliplatin-resistant, thus be excluded that the medicine.Following medicine is selected to carry out parallel drug sensitive experiment：Buddhist nun is not
Department spit of fland, doxifluridine, Tegafur, Carmofur, UFT, capecitabine, epirubicin, mitomycin, shellfish cut down pearl
Monoclonal antibody, Victibix, Cetuximab.
Wherein, UFT, Victibix, mitomycin, capecitabine suppress growth of tumour cell effect compared with
It is good.
Step 6：By preferred parallel drug sensitive experiment scheme, patients clinical medication is instructed
It is described to instruct patients clinical therapeutic regimen to be to draw preferred scheme based on step 5, that is, select UFT,
Victibix, mitomycin, capecitabine.Final doctor, which have selected mitomycin, to be used to treat, and its medication guide is with reference to selected
The operation instruction of clinical medicine is carried out.
Step 7：After one course for the treatment of, patient's 5-10ml peripheral bloods are extracted
The time of a described course for the treatment of, depending on the clinical medicine operation instruction selected in step 6.Described extraction
The quantity of patient's 5-10ml peripheral bloods, the quantity that Ying Yuqian once extracts patient's peripheral blood is consistent, such as same to extract 7.5ml.
It is to have a unified contrast condition to carry out CTC assessments before and after treating using unified peripheral blood extraction amount.
Step 8：Separate CTC circulating tumor cells
The separation CTC circulating tumor cells, method is with step 2, using same separation method and condition, to carry out
CTC, which is assessed, before and after treatment a unified contrast condition.
Step 9：Assess
(1) a period of time does not detect CTC, and the state of an illness is controlled, and patient enters observation state；(2) detect CTC, repeat with
Upper step 4 and later step；(3) CTC is not detected, is continuing with clinical application scheme.
Appraisal procedure, condition described in step 9 are all carried out according to step 3, also for unified appraisal procedure.At one section
Between do not detect CTC when assessing, can determine that course for the treatment of progress is good, point out the diffusion of patient's tumour to be controlled.Described a period of time,
Depending on the state of an illness and medicine, continuous three treatment times of clinical medicine generally used are advisable.I.e. generally, continuous three
After the individual clinical medicine course for the treatment of used do not detect when CTC circulating tumor cells are assessed, you can be determined as that the state of an illness obtains stabilization
Control.Once detecting CTC, 4 will be repeated the above steps, into CTC circulating tumor cells in vitro culture, amplification step, Jin Erji
Continuous step 5-9 all flows, into diagnosis and treatment circulation.Once, it is secondary not detect CTC, can continue to adopt preferred clinic
Therapeutic regimen.
The patient is after three courses for the treatment of, and CTC circulating tumor cells still have, therefore continues parallel drug sensitive experiment, the disease
People produces resistance to a certain degree to mitomycin, abandons the medicine, by continuing parallel drug sensitive experiment, doctor's selection capecitabine
It is used as medicine.After three courses for the treatment of, CTC circulating tumor cells are significantly reduced.
Because the application method is before medication, drug sensitive experiment was carried out, therefore resistance can be avoided to greatest extent
Medication is invalid caused by property, and experiment shows, except the serious tumor patient of only a few resistance,>99.9% patient can pass through
The present processes find accurately treatment method, wherein there is the middle and advanced stage patient of part resistance, pass through the side of the application
Method obtains good therapeutic effect, compared to traditional chemotherapy means, life span extension 25-36%, while the poison of medicine is secondary
Effect substantially reduction, hence it is evident that improve life quality.
Specific embodiment of the utility model is described in detail above, but it is intended only as example, and this practicality is new
Type is not restricted to particular embodiments described above.To those skilled in the art, it is any that the utility model is carried out
Equivalent modifications and substitute also all among category of the present utility model.Therefore, spirit of the present utility model and model are not being departed from
Enclose lower made impartial conversion and change, should all cover in the range of the utility model.
Claims (10)
1. a kind of device for the accurate treatment method of tumour based on CTC circulating tumor cells, it is characterised in that including：
--- shell, the shell is provided with hole, for patient's peripheral blood of extraction to be added；
--- CTC circulating tumor cell separation equipments, for separating CTC circulating tumor cells from the peripheral blood added；
--- CTC circulating tumor cell detection devices, the CTC circulating tumor cell separated for detecting；
--- closed CTC circulating tumor cells culture device, it is external for separated CTC circulating tumor cells to be carried out
Culture, propagation；
--- susceptibility detection device, carry out drug sensitive experiment for the CTC circulating tumor cells to culture.
2. device according to claim 1, it is characterised in that the internal cavities of the shell are provided with the reception peripheral blood
Detect and the first pan straddle is provided with the first container of sample, the shell, for placing the first container, the first container branch
Frame can rotate about axle rotation；First pan straddle is provided with multiple first container standing grooves, multiple first container standing grooves
Around rotary shaft arrangement.
3. device according to claim 1, it is characterised in that described device includes second container, is isolated for receiving
The CTC circulating tumor cells come.
4. device according to claim 3, it is characterised in that described device includes second container transmission equipment, for inciting somebody to action
The second container successively or is respectively transmitted to CTC circulating tumor cells detection device, CTC circulating tumor cells culture device.
5. device according to claim 4, it is characterised in that the second container transmission equipment takes out including first end
Part, for being taken out second container, being placed on second container transmission equipment；And/or the second container transmission equipment includes
Second end removal piece, for the second container on second container transmission equipment to be taken out, is placed into the detection of CTC circulating tumor cells
In equipment and/or CTC circulating tumor cell culture devices.
6. device according to claim 1, it is characterised in that the CTC circulating tumor cells culture device and the medicine
Quick detection device share one can closed chamber, it is described that thermoregulator, content of nitrogen dioxide inspection can be provided with closed chamber
Survey device, gas inlet and outlet, liquid material and add mouth；It is described can closed chamber be provided with watch window, or, it is described can closed chamber
Provided with shooting and/or photographing device.
7. device according to claim 6, it is characterised in that provided with it is multiple can closed chamber, each can closed chamber
It is interior that one or more CTC circulating tumor cells culture devices and the susceptibility detection device are set.
8. device according to claim 7, it is characterised in that provided with transport channel by it is the multiple can closed chamber connect
Connect, for by second container send into it is expected can be in closed chamber.
9. device according to claim 1, it is characterised in that described device includes processor, data output apparatus, described
Processor manipulates data output apparatus and exports CTC circulating tumor cells testing result and/or drug sensitive experiment result, or described
CTC circulating tumor cell testing results can be converted to disease condition and/or can change drug sensitive experiment result by processor
Exported for patients clinical medication guide scheme.
10. device according to claim 9, it is characterised in that described device also includes holder, for storing from disease
The detection data of each peripheral blood sample of people, before each peripheral blood sample detection and/or after detection, the processor reads same
The detection data of peripheral blood sample before patient, and contrasted and/or exported in the lump with it.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201621378586.6U CN206385173U (en) | 2016-12-15 | 2016-12-15 | Device for the accurate treatment method of tumour based on CTC circulating tumor cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201621378586.6U CN206385173U (en) | 2016-12-15 | 2016-12-15 | Device for the accurate treatment method of tumour based on CTC circulating tumor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN206385173U true CN206385173U (en) | 2017-08-08 |
Family
ID=59487985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201621378586.6U Active CN206385173U (en) | 2016-12-15 | 2016-12-15 | Device for the accurate treatment method of tumour based on CTC circulating tumor cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN206385173U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106957799A (en) * | 2016-12-15 | 2017-07-18 | 郭昊伦 | A kind of device for the accurate treatment method of tumour based on CTC circulating tumor cells |
-
2016
- 2016-12-15 CN CN201621378586.6U patent/CN206385173U/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106957799A (en) * | 2016-12-15 | 2017-07-18 | 郭昊伦 | A kind of device for the accurate treatment method of tumour based on CTC circulating tumor cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102510719B (en) | Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent | |
| CN104471057A (en) | Modified bacteria and uses thereof for treatment of cancer or tumor | |
| CN107976534A (en) | A kind of quick drug effect screening technique of antitumor drug and its special purpose device | |
| WO2018107418A1 (en) | Tumor accurate treatment method and apparatus based on circulating tumor cell | |
| CN108310014A (en) | A kind of stem cell medicine and preparation method thereof and the application in the drug for preparing prevention injury of lungs | |
| CN106957799A (en) | A kind of device for the accurate treatment method of tumour based on CTC circulating tumor cells | |
| CN206385173U (en) | Device for the accurate treatment method of tumour based on CTC circulating tumor cells | |
| CN102391992A (en) | Monoclonal antibody for resisting human NSCLC and application of monoclonal antibody | |
| CN102413875A (en) | Method to treat psoriasis and other hyperproliferative skin disorders | |
| CN106236318A (en) | The construction method of the echinococcosis multilocularis animal model of Echinococcus multilocularis THPV approach infected liver | |
| CN109929797A (en) | Chicken embryo Transplanted tumor model method for building up and its application in drug susceptibility detection | |
| CN103751221B (en) | The application in the medicine of preparation treatment liver cancer of the SIRT1 inhibitor associating Sorafenib | |
| Phung et al. | In-vitro and in-vivo assays for angiogenesis-modulating drug discovery and development | |
| CN107753143A (en) | Build the method and system of gastric lymphoma animal model | |
| CN106344609A (en) | Application of ozonized oil in preventing and controlling nervous system diseases | |
| CN102908356A (en) | Application of geniposide | |
| CN110959579A (en) | Construction method and application of patient-derived lymphoma immunodeficiency mouse transplantation tumor model | |
| Paylian et al. | Potential threapeutic applications of extract made from electroporated xenopus laevis frog oocytes in murine models of melanoma, traumatic brain injury and experimental skin wrinkling | |
| CN104825507A (en) | Radix actinidiae chinensis extract and application thereof in preparation of drugs for treating bile duct cancer | |
| CN100528174C (en) | Combination of cytidine disodium triphosphate and arginine, and preparation method thereof | |
| CN109223801A (en) | A kind of new the killing agent of gastric cancer tumor stem cell and its application | |
| CN107349191A (en) | Application of the Vorinostat in the medicine for preparing treatment lung cancer | |
| CN110237091A (en) | A kind of hyaluronic acid maintenance biomembrane can be used for children | |
| CN110495424A (en) | A kind of construction method of synovial sarcoma xenograft mouse model | |
| CN106138045B (en) | Tumor microenvironment is manipulated by targeting mTOR to eliminate the method and preparation of drug resistance of tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |